J-P. Machiels underlines importance of EGFR target in head and neck cancer, because monoclonal antibodies against the EGFR improve outcome. However a limitation with anti-EGFR therapy exist, as a minority of the patients will have objective response and the problem in head and neck cancer, compared to other cancers, is that we don’t have any predictive biomarker. He further discusses the differences at the molecular level between HPV-positive and negative disease. Regarding immunotherapy in head and neck cancer, the interesting period is on horizon.